Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial

The combination of neoadjuvant durvalumab and olaparib shows therapeutic activity in bladder cancer. Resistance mechanisms seem to be driven by transcriptional adaptations rather than the emergence of new mutations.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-04-21
DOI
https://doi.org/10.1158/1078-0432.ccr-24-2890
Citations
1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
2.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial

Jesús García-Donás, Rodrigo Madurga, Cristina Rodríguez‐Antona, Albert Font et al.
1 citations
Clinical Cancer Research
Bladder and Urothelial Cancer Treatments
2.01
article

Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial

Jesús García-Donás, Rodrigo Madurga, Cristina Rodríguez‐Antona, Albert Font, Elena Sevillano-Fernández, Carlos Álvarez-Fernández, Juan Francisco Rodríguez-Moreno, Ricardo Fernández, Luis Beltrán, Sergio Ruiz‐Llorente, Pedro Berraondo, Pablo Gajate, Ricardo Collado, Osvaldo Graña‐Castro, Núria Laínez, Guillermo de Velasco, Juan Antonio Virizuela, Sergio Vázquez
article en
1 citations

Abstract

The combination of neoadjuvant durvalumab and olaparib shows therapeutic activity in bladder cancer. Resistance mechanisms seem to be driven by transcriptional adaptations rather than the emergence of new mutations.

Clinical Cancer ResearchVol. 31(9)
Universidad San Pablo CEU (ES), Institut Català d'Ornitologia (ES), Universidad de Alcalá (ES), Barts Health NHS Trust (GB), Universidad Francisco de Vitoria (ES), Spanish National Cancer Research Centre (ES), Hospital Universitario Virgen Macarena (ES), Complejo Hospitalario de Navarra (ES), Hospital Universitario 12 De Octubre (ES), Institut Català d'Oncologia (ES), Navarre Institute of Health Research (ES), HM Hospitales (ES), Hospital Universitario Central de Asturias (ES), Hospital de Cruces (ES), Hospital Universitario HM Sanchinarro (ES), Hospital Universitario Lucus Augusti (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Complejo Hospitalario de Cáceres (ES), Hospital Universitario Ramón y Cajal (ES), Universidad de Navarra (ES)
Good health and well-being
Openalex Percentile: Top 17%
Bladder and Urothelial Cancer Treatments
2.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.